Page 48 - Neuropsychiatric.indd

14. นฤมล เจริญศิริพรกุล. การแพ้ยา อาการไม่พึงประสงค์จากยาที่เกิดต่อผิวหนังและตับ. 2561 31. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64(1):
15. Tisdale JE, Miller DA. Drug-Induced Diseases: Prevention, Detection, and Management. 393-406.

United States: American Society of Health-System Pharmacists, Inc., 2018. 32. Bazil CW, Pedley TA. Clinical pharmacology of antiepileptic drugs. Clin Neuropharmacol.
16. Dipiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V. Pharmacotherapy: A 2003;26(1):38-52.
pathophysiologic approach. 11th ed. United States: McGraw Hill Companies, Inc, 2020. 33. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic
17. Choudhury A, Sahu T, Ramanujam PL, Banerjee AK, Chakraborty I, Kumar K, et al. properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet.

Neurochemicals, behaviours and psychiatric perspectives of neurological diseases. 2002;41(4):261-309.
Neuropsychiatry (London). 2018;8(1):395-424. 34. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(2
18. Sheffler ZM, Reddy V, Pillarisetty LS. Physiology, Neurotransmitters. [accessed 10 May Suppl):S133-53.

2021]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539894/#_article- 35. Guina J, Merrill B. Benzodiazepines I: upping the care on downers: the evidence of risks,
25841_s4_. benefits and alternatives. J Clin Med. 2018;7(2):17.
19. Seethalakshmi D. Neurotransmitters and their impact on mental illness. IJSR. 36. Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use.
2017;6(5):1512-8. Drugs. 1994;48(1):25-40.
20. Pickar D, Litman RE, Konicki PE, Wolkowitz OM, Breier A. Neurochemical and neural 37. Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr.

mechanisms of positive and negative symptoms in schizophrenia. Mod Probl 2015;38(5):152-5.
Pharmacopsychiatry. 1990;24:124-51. 38. Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future.
21. Cowen PJ. Neuroendocrine and neurochemical process in depression. Psychopathology Neurotoxicology. 2004;25(1-2):215-21.

Review. 2016;3(1):3-15. 39. Aboukarr A, Giudice M. Interaction between monoamine oxidase B Inhibitors and selective
22. Kaur S, Singh R. Role of different neurotransmitters in anxiety: a systematic review. Int J serotonin reuptake inhibitors. Can J Hosp Pharm. 2018;71(3):196-207.
Pharm Sci Res. 2017;8(2):411-21. 40. Livingston MG, Livingston HM. Monoamine oxidase inhibitors. An update on drug
23. Sarter M, Bruno J, Parikh V. Abnormal neurotransmitter release underlying behavioral and interactions. Drug Saf. 1996;14(4):219-27.

cognitive disorders: toward concepts of dynamic and function-specific ys 41. Finley PR. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential
regulation. Neuropsychopharmacol. 2007;32:1452–61. therapeutic distinctions. Ann Pharmacother. 1994;28(12):1359-69.
24. Akyuz E, Polat AK, Eroglu E, Kullu I, Angelopoulou E, Paudel YN. Revisiting the role of 42. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake
neurotransmitters in epilepsy: An updated review. Life Sci. 2021;265:118826. inhibitors. Int Clin Psychopharmacol. 1996;11 (Suppl 5):31-61.

25. Doummar D, Moussa F, Nougues MC, Ravelli C, Louha M, Whalen S, et al. Monoamine 43. Gabriel M, Sharma V. Antidepressant discontinuation syndrome. CMAJ. 2017;189(21):E747.
neurotransmitters and movement disorders in children and adults. Rev Neurol (Paris). 44. Massabki I, Abi-Jaoude E. Selective serotonin reuptake inhibitor ‘discontinuation syndrome’
2018;174(9):581-8. or withdrawal. BJPsych. 2021:218(3):168-71.
26. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central 45. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions

nervous system-mediated effects. Ochsner J. 2013;13(2):214-23. updated. Br J Pharmacol. 2007;151(6):737-48.
27. Fasipe OJ. Neuropharmacological classification of antidepressant agents based on their 46. Haddad P, Anderson I. Recognising and managing antidepressant discontinuation
mechanisms of action. Arch Med Health Sci 2018;6:81-94. symptoms. Adv Psychiatr Treat. 2007:13(6):447-57.
28. Sub Laban T, Saadabadi A. Monoamine oxidase inhibitors (MAOI). [accessed 10 May 2021]. 47. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety,

Available from: https://www.ncbi.nlm.nih.gov/books/NBK539848/ tolerability, and risks associated with first- and second-generation antipsychotics: a state-
29. Chu A, Wadhwa R. Selective serotonin reuptake inhibitors. [accessed 11 May 2021]. of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757-77.
Available from: https://www.ncbi.nlm.nih.gov/books/NBK554406/ 48. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician.
30. Moraczewski J, Aedma KK. Tricyclic antidepressants. [accessed 11 May 2021]. Available 2010;81(5):617-22.

from: https://www.ncbi.nlm.nih.gov/books/NBK557791/

26 27
27